Michael O’Shea

Hiker, music, running. IM resident Mayo AZ '25, Cards Fellow Mayo MN '28, Irish transplant in the US🇮🇪🇪🇺🏳️‍🌈🇺🇸. Sé/é, níl iontu ach mo thuairimí féin

[Michael O’Shea @DrMPOShea]

How safe are DOACs in Tetralogy of Fallot and PA-IVS?

We found ~5× higher bleeding with DOACs vs warfarin, particularly in patients with worse RV function.

Read our latest original research in @HRS_O2Journal 👇https://t.co/THPuviHfwC

[Marc Porter Magee 🎓 @marcportermagee]

1% of all physicians accounted for 32% of all medical malpractice claims paid

[mandeep singh @mandeep_mayo]

My summary slide. Follow these simple principles in life and you will enjoy your career as an interventional cardiologist

[Updates in Medicine @medic_updates]

Aspirin’s long reign after PCI may be over—HOST-EXAM shows clopidogrel wins at 10 years.

[NEJM @NEJM]

Presented at #ACC26:

Among patients with a preserved ejection fraction at least 1 year after myocardial infarction, stopping beta-blockers was noninferior to continuing therapy with respect to major clinical outcomes. Full SMART-DECISION trial results: https://t.co/dZS03RaTcA

@ACCinTouch

[C. Michael Gibson MD @CMichaelGibson]

HOST-EXAM trial 10-year results: Clopidogrel monotherapy is superior to aspirin for chronic maintenance after PCI, significantly reducing both thrombotic and bleeding events. #ACC26 View slides here: https://t.co/ihoudzlxIi

[Dr. Purvi Parwani @purviparwani]

#CHIP-BCIS3
Patients: Stable patients, No Anterior STEMI, No Cardiogenic Shock
🚫 Primary endpoint negative — win ratio 0.85 (no benefit signal)
⚠️ Mortality concern — higher CV death with Impella (HR 1.91)
➖ No consistent efficacy — MI, stroke, hospitalization largely neutral
🩸 Safety penalty — more bleeding & vascular complications
🧠 Take-home — Standard of Care remains the standard, Impella- no clinical benefit + possible harm → rethink routine use of elective Unloading with "protected" PCI

#ACC26

@mmamas1973 @mirvatalasnag @hollymorgs

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

The placebo-controlled PCI debate returns this time with the 1st RCT blinded sham PCI trial for CTO 👏🏽👏🏽

#ORBITA-CTO evaluates PCI vs placebo in chronic total occlusions

➡️ Key results:
🎷CTO PCI ⤵️ angina frequency: immediate, sustained & consistent with OR=4.38 of improved angina symptoms & led to ~30 days angina free days

50 patients randomized, daily recording of angina episodes with app

#ACC26 #CTO #Cardiotwitter #LBCT @JACCJournals #orbitacto

[NEJM @NEJM]

Early surgery in asymptomatic patients with very severe aortic stenosis led to a lower risk of a composite of operative mortality or death from cardiovascular causes at 10 years than conservative care. Full RECOVERY trial results: https://t.co/tLqC25ccCJ

[Aamir Laghari , MD, FACC @DrAamirLaghari]

1 minute review for top 10 changes in 2026 lipid guidelines 🫀

Shared decision making always worked for me , patient compliance is great when you give them autonomy and a plan for decade !
@ACCinTouch

[Mayo Clinic Rochester Cardiology Fellows @MayoCVFellows]

Congratulations to the newly matched @MayoCVFellows❤️‍🔥📚🩺!

A remarkable new chapter awaits, with profound clinical moments, memorable wins, and mentorship that truly shapes careers. Excited to see your journeys unfold!

Welcome to @MayoClinic @MayoClinicCV!

[Michael O’Shea @DrMPOShea]

Check out our latest paper - RV hypertension could explain DOAC bleeding discrepancies: Echocardiographic hemodynamics correlate with differences in DOAC-specific bleeding and stroke rates in non-valvular atrial fibrillation | BMC Cardiovascular Disorders https://t.co/wGksOkgvFO

[Michael O’Shea @DrMPOShea]

CLOSURE-AF at @AHAScience
A major blow to LAAO as an alternative to DOACs?

[Michael O’Shea @DrMPOShea]

Here’s a fantastic bit of journalism on the cause of food deserts - ⁦@99piorg⁩ https://t.co/z3ju89DglA

[Michael O’Shea @DrMPOShea]

@MayoClinicNepAZ @BhavnaBhasin1 @HommosMusab @SamiAlasfar @keddis_mira Dream team!!

[Dan Choi, MD, FAAOS @drdanchoi]

🚨 New AMA data confirms it: fewer than half of U.S. physicians are now in private practice.

Just 42.2% in 2024, down from 60.1% in 2012.

Let’s unpack the trends, what’s driving the decline, and why it matters for physicians & patients 🧵

[Michael O’Shea @DrMPOShea]

@EllauziRama Huge congratulations Rama! 👏

[Michael O’Shea @DrMPOShea]

DOAC use in Tetralogy of Fallot/PA-IVS with Afib/flutter was associated with a 5-fold higher rate of major bleeding events compared to warfarin. Is RV hypertension the culprit?
Check out our pre-print:
https://t.co/VNe5eaejxN
#ToF #ACHD @MayoAZ_IMRES @MayoCVFellows

[Michael O’Shea @DrMPOShea]

How important is myocardial scar in determining arrhythmia risk in high risk patients with hypertrophic cardiomyopathy?

Check out the latest paper in #AmericanHeartJournal https://t.co/33zos6fD1R
@SrekarRavi @omarjavedbaqal @hcmsociety @societyhcm

[Michael O’Shea @DrMPOShea]

We surveyed internal medicine, neurology, & transitional residents on research education needs. Results highlight key gaps—& how programs can better support scholarly success
Read more 👉 https://t.co/KZWBGkh8HQ
#MedEd #MedTwitter #ResidencyResearch
@MayoAZ_IMRES @MayoAZneurores